

.png)
Understand. Prevent. Cure.
At the Johns Hopkins Greenberg Bladder Cancer Institute, we practice multi-disciplinary care for every single patient. This means that the entire care team works closely together to make an accurate diagnosis and develop individualized treatment plans.
From proven protocols to promising clinical trials, you have options. We'll educate and guide you.
At the GBCI, our specialized team is developing new therapies and approaches to UTUC.
Learn more about our Women's Bladder Cancer Program, or register for our upcoming women-run support groups.
The Greenberg Bladder Cancer Institute offers specialized clinical services for patients and families with all types, and at any stage of bladder cancer.
More specifically, we offer In-person clinical appointments for both newly diagnosed and recurrent, non-muscle invasive bladder cancer (NIMBC), muscle-invasive bladder cancer (MIBC), and upper tract urothelial cancer (commonly referred to as UTUC). We also offered specialized clinical care for women with bladder cancers.
We offer several clinical locations in the Baltimore and in the National Capital Region.
Unfortunately, we do not conduct initial consults through telemedicine. We are also unable to provide telemedicine to out of state patients or informally comment on a treatment plan.
We also offer pathology second opinions - more here.
From proven protocols to promising clinical trials, you have options. We'll educate and guide you.
Ongoing support can help patients and their families throughout the bladder cancer journey.
The Johns Hopkins Greenberg Bladder Cancer Institute (GBCI) is making a significant impact on bladder cancer treatment, focusing on developing a cure through research. Our multidisciplinary, collaborative clinical approach utilizes innovative strategies - including the genetic sequencing of individual tumors - to provide more treatment choices to patients and help improve outcomes. Advances at the GBCI are having a ripple effect on bladder cancer treatment advances worldwide.
Bladder Cancer | Q&A with Urologist Max Kates, M.D.
Bladder Cancer | Q&A with Surgeon Armine Smith, M.D.
David J. McConkey, Ph.D. is the inaugural director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medicine. His mission is to make the Institute a hub of an institutional and international community of researchers who share a commitment to advancing the scientific understanding of bladder cancer and improving its treatment.
Dr. Jean Hoffman-Censits discusses the specific impacts of bladder cancer on women on the Johns Hopkins Woman’s Health podcast.
Highlights from Dr. David McConkey's Visit to the Jack Birch Unit at the York Biomedical Research Institute
We're making progress. Can you help us get there faster? See what your gift can do and donate today.